SCHEMBL7678963

SCHEMBL7678963

CCCc1csc(C(=O)OC)c1N

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.61
KMT2A Q03164 4/20 0.61
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
HTR1A P08908 1/20 0.40
SCN1A P35498 1/20 0.40
SCN2A Q99250 1/20 0.40
SCN3A Q9NY46 1/20 0.40
MAPT P10636 4/20 0.39
ALDH1A1 P00352 3/20 0.39
MEN1 O00255 2/20 0.39
GAA P10253 2/20 0.39
GLA P06280 2/20 0.39
HPGD P15428 2/20 0.39
ALOX15 P16050 2/20 0.39
HSD17B10 Q99714 2/20 0.39
ATM Q13315 1/20 0.39
POLB P06746 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7688016 0.88 KDM4E (0.57) KDM4EKMT2ACYP1A2CYP3A4HTR1A
SCHEMBL23459815 0.79 KMT2A (0.49) KDM4EKMT2ACYP1A2MAPTALDH1A1
SCHEMBL3369562 0.75 KDM4E (0.58) KDM4EKMT2AMAPTALDH1A1MEN1
SCHEMBL7029618 0.74 MAPT (0.46) KDM4EKMT2ACYP1A2CYP3A4MAPT
SCHEMBL1845347 0.74 KDM4E (0.57) KDM4EKMT2ACYP1A2CYP3A4HTR1A
SCHEMBL3230676 0.74 KDM4E (0.57) KDM4EKMT2AMAPTALDH1A1MEN1
SCHEMBL163725 0.74 KDM4E (0.57) KDM4EKMT2ACYP1A2CYP3A4HTR1A
SCHEMBL23460209 0.74 KDM4E (0.57) KDM4EKMT2AMAPTALDH1A1MEN1
SCHEMBL7033145 0.73 ALDH1A1 (0.50) KDM4EKMT2ACYP1A2CYP3A4MAPT
SCHEMBL6625082 0.73 KMT2A (0.57) KMT2ACYP1A2MAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6339089-B2 ANTIHYPOXIC AGENTS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; VASOCONSTRICTION; REDUCES BLOOD PARTIAL PRESSURE OF CARBON DIOXIDE; RESPIRATORY DISORDERS; UNDER OXYGEN INHALATION TREATMENT FUJIREBIO INC. (JP) 2002-01-15 US disclosed
US-20010006969-A1 PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME FUJIREBIO INC. (FUJIREBIO KABUSHIKI KAISHA) (JP) 2001-07-05 US disclosed
EP-0899263-A2 Fused pyrimidine derivatives and medicaments thereof for a blood oxygen partial pressure amelioration Fujirebio Inc. (JP) 1999-03-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010006969-A1 PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME CYP11B2, CYP11B1, OAT KDM4E 2446/4885KMT2A 948/4885CYP1A2 1299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.